Articles with public access mandates - Marwan FakihLearn more
Not available anywhere: 7
The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity
J Canon, K Rex, AY Saiki, C Mohr, K Cooke, D Bagal, K Gaida, T Holt, ...
Nature 575 (7781), 217-223, 2019
Mandates: US Department of Energy, US National Institutes of Health, Howard Hughes …
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
S Siena, M Di Bartolomeo, K Raghav, T Masuishi, F Loupakis, ...
The Lancet Oncology 22 (6), 779-789, 2021
Mandates: AIRC Foundation for Cancer Research in Italy
Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer
K Raghav, JM Loree, JS Morris, MJ Overman, R Yu, F Meric-Bernstam, ...
JCO Precision Oncology 3, 1-13, 2019
Mandates: US National Institutes of Health, National Institute for Health Research, UK
A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors
MG Fakih, L Pendyala, W Brady, PF Smith, ME Ross, PJ Creaven, ...
Cancer chemotherapy and pharmacology 62, 499-508, 2008
Mandates: US National Institutes of Health
Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N 1, N 11 diethylnorspermine
S Hector, R Tummala, ND Kisiel, P Diegelman, S Vujcic, K Clark, M Fakih, ...
Cancer chemotherapy and pharmacology 62, 517-527, 2008
Mandates: US National Institutes of Health
Phase Ib trial of mFOLFOX6 and everolimus (NSC-733504) in patients with metastatic gastroesophageal adenocarcinoma
V Chung, P Frankel, D Lim, C Yeon, L Leong, J Chao, N Ruel, ...
Oncology 90 (6), 307-312, 2016
Mandates: US National Institutes of Health
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
MW Saif, CR Becerra, MG Fakih, W Sun, L Popovic, S Krishnamurthi, ...
Cancer Chemotherapy and Pharmacology 88 (3), 485-497, 2021
Mandates: US National Institutes of Health
Available somewhere: 65
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ...
The Lancet Oncology 21 (2), 271-282, 2020
Mandates: US National Institutes of Health, Alex's Lemonade Stand
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, ...
New England Journal of Medicine 383 (13), 1207-1217, 2020
Mandates: US National Institutes of Health, Damon Runyon Cancer Research Foundation …
Colon cancer
PF Engstrom, JP Arnoletti, AB Benson, YJ Chen, MA Choti, HS Cooper, ...
Journal of the National Comprehensive Cancer Network 7 (8), 778-831, 2009
Mandates: US National Institutes of Health
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
F Meric-Bernstam, H Hurwitz, KPS Raghav, RR McWilliams, M Fakih, ...
The Lancet Oncology 20 (4), 518-530, 2019
Mandates: US National Institutes of Health
Geriatric assessment–driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial
D Li, CL Sun, H Kim, E Soto-Perez-de-Celis, V Chung, M Koczywas, ...
JAMA oncology 7 (11), e214158-e214158, 2021
Mandates: US National Institutes of Health
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
DA Fabrizio, TJ George Jr, RF Dunne, G Frampton, J Sun, K Gowen, ...
Journal of gastrointestinal oncology 9 (4), 610, 2018
Mandates: US National Institutes of Health
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the …
E Van Cutsem, S Huijberts, A Grothey, R Yaeger, PJ Cuyle, E Elez, ...
Journal of clinical oncology 37 (17), 1460-1469, 2019
Mandates: US National Institutes of Health, Dutch Cancer Society
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301
AA Miller, DJ Murry, K Owzar, DR Hollis, EB Kennedy, G Abou-Alfa, ...
Journal of Clinical Oncology 27 (11), 1800-1805, 2009
Mandates: US National Institutes of Health
Treatment of metastatic colorectal cancer: ASCO guideline
VK Morris, EB Kennedy, NN Baxter, AB Benson III, A Cercek, M Cho, ...
Journal of Clinical Oncology 41 (3), 678-700, 2023
Mandates: US National Institutes of Health, A*Star, Singapore
Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study
J Strosberg, N Mizuno, T Doi, E Grande, JP Delord, R Shapira-Frommer, ...
Clinical cancer research 26 (9), 2124-2130, 2020
Mandates: US National Institutes of Health
Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity
WW Ma, MW Saif, BF El‐Rayes, MG Fakih, TH Cartwright, JA Posey, ...
Cancer 123 (2), 345-356, 2017
Mandates: US National Institutes of Health
Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
A Marabelle, MG Fakih, J Lopez, M Shah, R Shapira-Frommer, ...
Annals of oncology 30, v477-v478, 2019
Mandates: Swiss Cancer League
A phase I/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105
A Drilon, S Fu, MR Patel, M Fakih, D Wang, AJ Olszanski, D Morgensztern, ...
Cancer discovery 9 (3), 384-395, 2019
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program